World J Gastroenterol. 2011 July 14; 17(26): 3082-3091.
Published online 2011 July 14. doi: 10.3748/wjg.v17.i26.3082.
Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk
Lucia Pacifico, Valerio Nobili, Caterina Anania, Paola Verdecchia and Claudio Chiesa.
Lucia Pacifico, Caterina Anania, Paola Verdecchia, Department of Pediatrics, Sapienza University of Rome, 00161-Rome, Italy
Valerio Nobili, Department of Hepato-gastroenterology and Nutrition, Pediatric Hospital “Bambino Gesù”, Rome, Italy
Claudio Chiesa, Institute of Translational Pharmacology, National Research Council, 00133-Rome, Italy
Author contributions: Pacifico L, Anania C and Chiesa C designed the study; Anania C, Verdecchia P and Nobili V were responsible for acquisition, analysis and interpretation of data; Pacifico L, Anania C and Verdecchia P drafted the manuscript; Pacifico L, Nobili V and Chiesa C prepared the final version of the manuscript; Chiesa C and Nobili V critically revised the manuscript for important intellectual content; all authors approved the final version of the manuscript.
Correspondence to: Claudio Chiesa, MD, Institute of Translational Pharmacology, National Research Council, Via del Fosso del Cavaliere, 100, I-00133 Rome, Italy. claudio.chiesa@ift.cnr.it
Telephone: +39-6-49979215 Fax: +39-6-49979216
Received February 2, 2011; Revised March 21, 2011; Accepted March 28, 2011;
Abstract
Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver histology severity and outcomes in the absence of chronic alcohol use. The mildest form is simple steatosis in which triglycerides accumulate within hepatocytes. A more advanced form of NAFLD, non-alcoholic steatohepatitis, includes inflammation and liver cell injury, progressive to cryptogenic cirrhosis. NAFLD has become the most common cause of chronic liver disease in children and adolescents. The recent rise in the prevalence rates of overweight and obesity likely explains the NAFLD epidemic worldwide. NAFLD is strongly associated with abdominal obesity, type 2 diabetes, and dyslipidemia, and most patients have evidence of insulin resistance. Thus, NAFLD shares many features of the metabolic syndrome (MetS), a highly atherogenic condition, and this has stimulated interest in the possible role of NAFLD in the development of atherosclerosis. Accumulating evidence suggests that NAFLD is associated with a significantly greater overall mortality than in the general population, as well as with increased prevalence of cardiovascular disease (CVD), independently of classical atherosclerotic risk factors. Yet, several studies including the pediatric population have reported independent associations between NAFLD and impaired flow-mediated vasodilatation and increased carotid artery intimal medial thickness-two reliable markers of subclinical atherosclerosis-after adjusting for cardiovascular risk factors and MetS. Therefore, the rising prevalence of obesity-related MetS and NAFLD in childhood may lead to a parallel increase in adverse cardiovascular outcomes. In children, the cardiovascular system remains plastic and damage-reversible if early and appropriate interventions are established effectively. Therapeutic goals for NAFLD should address nutrition, physical activity, and avoidance of smoking to prevent not only end-stage liver disease but also CVD.
Keywords: Nonalcoholic fatty liver disease, Metabolic syndrome, Cardiovascular risk, Children
INTRODUCTION
Over the last two decades, the rise in the prevalence rates of overweight and obesity may explain the emergence of nonalcoholic fatty liver disease (NAFLD) as the leading cause of liver disease in pediatric populations worldwide[1]. NAFLD comprises a disease spectrum ranging from simple steatosis to steatohepatitis (NASH), with varying degrees of inflammation and fibrosis, progressing to end-stage liver disease with cirrhosis and hepatocellular carcinoma[2,3]. NAFLD affects from 2.6% to 9.8% of children and adolescents, and this figure increases up to 74% among obese individuals[4-8]. NAFLD is strongly associated with obesity, insulin resistance, hypertension, and dyslipidemia, and is now regarded as the liver manifestation of the metabolic syndrome (MetS)[9], a highly atherogenic condition. When compared to control subjects who do not have steatosis, patients with NAFLD have a higher prevalence of atherosclerosis, as shown by increased carotid wall intimal thickness, increased numbers of atherosclerotic plaques, and increased plasma markers of endothelial dysfunction, that are independent of obesity and other established risk factors[10-13]. Consistent with these observations natural history studies have reported that the increased age-related mortality observed in patients with NAFLD is attributable to cardiovascular as well as liver-related deaths[14-17].
Pathologic studies have shown that atherosclerosis is an early process beginning in childhood, with fatty streaks observed in the aorta and the coronary and carotid arteries in children and adolescents[18,19]. There is a positive correlation between the extent of early atherosclerotic lesions in the aorta and the coronary and carotid arteries and cardiovascular risk factors, including obesity, dyslipidemia, hypertension, and diabetes[20-22]. Yet the exposure to cardiovascular risk factors of children and adolescents is independently associated with an increased carotid atherosclerosis in early to middle adulthood[23,24]. Thus, the possible impact of NAFLD on cardiovascular disease (CVD) deserves particular attention in view of the implications for screening/surveillance strategies in the growing number of children and adolescents with NAFLD. In the present review, we examine the current evidence on the association between NAFLD and atherosclerosis in the pediatric population, discuss briefly the possible biological mechanisms linking NAFLD and early vascular changes, and address the approach to treatment of NAFLD to prevent not only end-stage liver disease but also CVD.
NAFLD AND THE METABOLIC SYNDROME
NAFLD is closely associated with abdominal obesity, atherogenic dyslipidemia, hypertension, insulin resistance and impaired glucose tolerance, which are all features of the MetS. Approximately 90% of patients with NAFLD have at least one of the features of MetS, and about 33% meet the complete diagnosis, placing NAFLD as the hepatic representation of MetS[25]. The relationship of NAFLD with MetS features has been confirmed in adults in several studies[9,26-29]. Evidence for a relationship between MetS and NAFLD in children is also emerging[30-32]. The Korean National and Nutrition Examination Survey found that participants aged 10-19 years who presented with three or more risk factors for MetS, had an odds ratio (OR) of 6.2 (95% CI, 2.3-16.8) for an elevated serum alanine aminotransferase (ALT), which they used as an indicator of fatty liver[30]. A single center study from Italy reported MetS to be present in 65.8% of children (3-18 years) with biopsy-proven NAFLD and found grade of fibrosis to be the only histological feature significantly associated with MetS on univariate analysis[31]. A case-control study comparing 150 overweight children with biopsy-proven NAFLD to 150 age-, sex-, and obesity-matched children without evidence of NAFLD, found that, after adjustment for age, sex, race, ethnicity, and hyperinsulinemia, children with MetS had an OR of 5.0 (95% CI, 2.6-9.7) for NAFLD compared with children without MetS[32]. This is the most compelling data to support a significant relationship between NAFLD and MetS, not explicable merely by the coexistence of overweight or obesity in these two conditions, and lend support to the hypothesis that fat accumulation in the liver has an important role in the pathogenesis of other obesity-related comorbidities[33].
NAFLD AND CARDIOVASCULAR DISEASE
Increases in morbidity and mortality from CVD are probably among the most important clinical features associated with NAFLD[13]. Published studies have shown that mortality among patients with NAFLD is higher than that in the general population, mainly due to concomitant CVD and liver dysfunction[14-17]. Using the resources of the Rochester Epidemiology Project, Adams et al[14] conducted a population-based cohort study to examine the natural history of patients diagnosed with NAFLD on the basis of imaging studies (83%) or liver biopsy (17%). Mean (SD) follow-up was 7.6 (4.0) years culminating in 3192 persons/years follow-up. Death occurred in 12.6% of patients and was most commonly due to malignancy and ischemic heart disease, which were also the two most common causes of death in the Minnesota general population of the same age and sex. Liver disease was also an important contributor of death among patients with NAFLD, being the third most common cause and accounting for 13% of all deaths. In contrast, “chronic liver disease and cirrhosis” was the 13th leading cause of death among the Minnesota general population, accounting for less than 1% of all deaths[14]. This implies that the increased overall mortality rate among NAFLD patients compared with the general population was at least in part due to complications of NAFLD. In a cohort study involving 129 consecutively enrolled patients diagnosed with biopsy-proven NAFLD, Ekstedt et al[15] compared survival and causes of death with a matched reference population. Mean follow-up (SD) was 13.7 (1.3) years. Mortality was not increased in patients with steatosis. In contrast, survival of patients with NASH was significantly reduced. A comparison of the causes of death of patients with NASH with those of the corresponding reference population showed it was significantly more common for patients with NASH to die from liver-related causes (2.8% vs 0.2%) and from cardiovascular disease (15.5% vs 7.5%). No significant differences in causes of death were found between non-NASH patients and the corresponding reference population[15]. In a cohort study involving 173 patients retrospectively identified as having a diagnosis of biopsy-proven NAFLD, Rafiq et al[16] showed that after a median follow-up of 18.5 years, patients with histologic NASH had significantly higher liver-related mortality than the non-NASH NAFLD cohort (17.5% vs 2.7%). The most common causes of death were coronary artery disease, malignancy, and liver-related death. In a very recent study involving a cohort of 118 subjects with NAFLD who underwent liver biopsy because of elevated liver enzymes, Söderberg et al[17] confirmed that, after a 28-year follow-up, overall survival was reduced in subjects with NASH, whereas bland steatosis with or without severe fibrosis was not associated with any increase in mortality risk in comparison with the general population. The main causes of death among patients with NAFLD were CVD, followed by extrahepatic cancers and hepatic diseases. All these data provide evidence of an increased risk for cardiovascular mortality in patients with NASH. However, most studies which examined the natural history of NAFLD were retrospective cohort studies with relatively small numbers of patients with histologically proven NAFLD who were seen at tertiary referral centers - features that limit the generalizability of the findings to a community-based practice where patients may have a milder disease. Indeed, among people with NAFLD, those who are referred to hepatologists may have a more advanced liver disease than those detected in the community or population based screening but are not referred. Therefore, the magnitude of mortality risk in NAFLD depends on the setting and method of ascertainment. Future longitudinal studies with larger and less selected cohorts of patients are needed to identify through reliable, noninvasive means the true impact of the wide spectrum of NAFLD in the general population on the long-term overall and cardiovascular mortality.
Data on the prognosis and clinical complications of NAFLD in children remain scant[3]. Although coronary artery disease and stroke usually occur in middle and late age, autopsy studies have shown that the atherosclerotic process in the vascular wall begins in childhood and is accelerated in the presence of risk factors[18-24]. Given the large number of children affected, it is imperative that we establish a better understanding of the natural history of pediatric NAFLD in terms of the progression of liver disease as well as its complications (including long-term cardiovascular risk profile). Feldstein et al[34] recently reported the first longitudinal study describing the long-term survival of children with NAFLD who underwent a follow-up of up to 20 years. That study demonstrated that NAFLD in children is a disease of progressive potential. Some children presented with cirrhosis, others progressed to advanced fibrosis or cirrhosis during follow-up, and some developed end-stage liver disease with the consequent need for liver transplantation. Feldstein et al[34] also showed that NAFLD in children is associated with significantly shorter long-term survival than the expected survival in the general population of the same age and sex. Children with NAFLD had a 13.8-fold higher risk of dying or requiring liver transplantation than the general population of the same age and sex. The recorded deaths were not liver-related.
Recent epidemiological studies in adult subjects have also demonstrated that NAFLD is associated with an increased risk of incident CVD that is independent of the risk conferred by traditional risk factors and components of the MetS[35-42]. Yet, several studies (including the pediatric population) have reported independent associations between NAFLD and impaired flow-mediated vasodilatation (FMD) and increased carotid-artery intimal medial thickness (cIMT) - two reliable markers of subclinical atherosclerosis - after adjusting for cardiovascular risk factors and MetS[10,12,43-47].
NAFLD AND MARKERS OF SUBCLINICAL ATHEROSCLEROSIS IN CHILDREN
The relation between obesity and atherosclerosis development has been evaluated in many pediatric studies[48], but few studies focused on the relation between NAFLD and atherosclerosis (Table 1)[32,47,49-56]. In an autopsy study involving 817 children (aged 2 to 19 years) who died of external causes (accident, homicide, suicide) from 1993 to 2003, Schwimmer et al[49] showed that the prevalence of atherosclerosis was increased by a factor of 2 among those with NAFLD. Atherosclerosis was assessed as absent, mild (aorta only), moderate (coronary artery streaks/plaques), or severe (coronary artery narrowing). Fatty liver was present in 15% of the children. For the entire cohort, mild atherosclerosis was present in 21% and moderate to severe atherosclerosis in 2%. Atherosclerosis was significantly more common in children with fatty liver than those without the disease (30% vs 19%, P < 0.001). Body mass index (BMI) was not independently correlated to the presence of atherosclerosis, but fatty liver status and BMI did interact significantly (P < 0.01). Consequently, for obese subjects the odds of having atherosclerosis was more than 6 times higher in children with fatty liver than those without[49].
Table 1
Table 1
Published studies on the association between nonalcoholic fatty liver disease and markers of atherosclerosis in the pediatric population
Despite this, there are currently few data regarding the possible association between liver histopathologic changes and atherogenic risk in children[32,52,56]. In the Bogalusa heart study in children, investigators found that the extent to which the intimal surface was covered with atherosclerotic lesions was significantly associated with elevation of concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), triglycerides (TG), and lower concentration of high-density lipoprotein cholesterol (HDL-c). Ratios of cholesterol ester-rich lipoprotein level (TC/HDL-c and LDL-c/HDL-c) are well-established predictors of C VD[57]. More recently, the TG/HDL-c ratio has been shown to be a strong predictor of MetS and CVD[58,59]. In a case-control study, Schwimmer et al[32] showed that children with a biopsy-proven NAFLD had a significantly higher fasting glucose, insulin, TC, LDL-c, TG, systolic and diastolic blood pressure than age-, sex-, and BMI-matched peers without NAFLD. These data confirm that fat accumulation in the liver may play a more important role than obesity itself in determining the risk for “weight-related” metabolic comorbidities[33]. Thus, the authors concluded that NAFLD may serve as a marker to stratify the cardiovascular risk of overweight and obese children and adolescents[32]. Furthermore, in a study involving 118 consecutive children with biopsy-proven NAFLD undergoing extensive metabolic profiling, Nobili and colleagues found that the NAFLD activity and fibrosis scores had a significant positive correlation with TG/HDL-c, TC/HDL-c, and LDL-c/HDL-c ratios[56]. After adjusting for potential confounders including BMI, homeostatic model assessment index, impaired glucose tolerance, and presence of MetS, both NAFLD activity score and stage of fibrosis remained independent predictors of an atherogenic lipid profile. The lipid ratios were found to be markedly higher in children with established NASH compared with those patients with simple steatosis or borderline disease, indicating that severity of liver injury in children with NAFLD is strongly associated with increased atherogenic risk[56].
Recent improvements in imaging technology have identified early vascular changes that can be assessed by the use of ultrasonography. These early changes include impairment of FMD, arterial stiffness, and increased cIMT. The measurement of FMD and cIMT by high-resolution ultrasound is increasingly used for cardiovascular risk evaluation in young individuals with obesity, MetS or its components, and pre-diabetes[23,60,61]. Pacifico et al[50] first showed that the severity of ultrasonographically diagnosed NAFLD in obese children was significantly associated with carotid atherosclerosis, independently of anthropometric and metabolic features. Demircioglu et al[51], in a subsequent study, also found an association between ultrasonographically detected NAFLD and cIMT measured at sites of the common carotid artery, carotid bulb and internal carotid artery. In addition, there was an increase in the mean of cIMT of each segment with the increase in hepatosteatosis grade[51]. Kelishadi et al[54] also demonstrated that cIMT was significantly associated with insulin resistance and NAFLD, suggesting that the liver and the vessels share common mediators. This is in contrast to the case-control study by Manco et al[52] including a mixed population of overweight and mildly obese children of whom 31 had biopsy-proven NAFLD, whereas 49 had no ultrasound evidence of NAFLD and no abnormal levels of aminotransferases. Although cIMT was statistically significantly higher on the left side in NAFLD cases, the authors concluded that this difference was unlikely to be clinically relevant because of the substantial overlap of cIMT values between cases and controls. Also, there were no differences in the frequency of MetS components between the groups. Finally, there was no association between histologic severity of NAFLD and cIMT[52]. However, a recent study by Patton et al [30] showed the potential power of MetS as a prognostic indicator of disease severity in NAFLD. Of the MetS features, central obesity and insulin resistance were most consistently associated with NAFLD histology[30].
The association between NAFLD and carotid atherosclerosis has also been determined in a large, randomly selected adolescent population from Reggio Calabria, a town in southern Italy[53]. The authors found that NAFLD, BMI, waist circumference, and systolic blood pressure were independent markers of increased cIMT. Likewise, in a very recent study with a large sample size it has been shown that obese children with NAFLD have a significantly lower FMD response and increased cIMT compared to obese children without NAFLD independently of other cardiovascular risk factors and MetS, and that obese children exhibit more functional and morphologic vascular changes than healthy lean controls, regardless of liver involvement[47]. The larger number of subjects in that study may in part account for the associations the authors were able to identify between NAFLD and functional vascular changes, in contrast to the study by Weghuber et al[55]. in which a very small sample of obese children with and without NAFLD had a similar FMD response.
Although longitudinal studies are needed to clarify the extent to which pediatric NAFLD and its severity influence long-term cardiovascular outcomes in the general population, overall the above cross-sectional findings suggest that childhood NAFLD is associated with early atherosclerosis.
POSSIBLE BIOLOGICAL MECHANISMS LINKING NAFLD AND ACCELERATED ATHEROSCLEROSIS
The biologic mechanisms by which NAFLD contributes to accelerated atherosclerosis, independently of other risk factors, are still poorly understood. Increased visceral adipose tissue and insulin resistance are the undisputed major contributors to NAFLD, MetS, and atherosclerosis[9,62,63]. The adipose tissue inflammation with consequent release of multiple proinflammatory molecules is one of the earliest steps in the chain of events involved in the development of insulin resistance and atherosclerosis, in particular in obese and overweight persons[64-66]. While insulin resistance promotes fatty acid accumulation in the liver, the latter causes hepatic insulin resistance characterized by a lack of suppression of endogenous liver glucose production. Therefore, NAFLD might act as a stimulus for further increased whole-body insulin resistance and dyslipidemia (with a characteristic overproduction of triglyceride- and cholesterol-rich remnant particles), leading to accelerated atherosclerosis[33]. It is also conceivable that other atherogenic mechanisms could be involved in patients with NAFLD including enhanced oxidative stress and chronic, subclinical inflammation, which are thought to be causal factors in the progression from simple steatosis to more advanced forms of NAFLD[27-29,62]. Indeed, patients with NAFLD frequently have higher plasma markers of oxidative stress and inflammation, at least partially derived from the diseased liver, as well as decreased adiponectin concentrations, an adipose-secreted cytokine with antiatherogenic properties[11,67-69].
Recent research has suggested a role for increased fructose consumption as a risk factor for NAFLD[70,71]. Strong evidence exists that fructose consumption may promote hepatic de novo lipogenesis and intrahepatic lipids, inhibition of mitochondrial β-oxidation of long-chain fatty acids, triglyceride formation and steatosis[72]. In addition, compared to glucose consumption, sustained dietary fructose has been reported to significantly increase plasma concentrations of fasting small dense LDL-c, oxidized LDL-c, and postprandial remnant-like-particle-triglyceride and -cholesterol in overweight and obese subjects[73]. These changes may be associated with increased risk of CVD[74,75].
Finally, NAFLD could be linked to accelerated atherogenesis through the presence of abnormal lipoprotein metabolism, especially during the post-prandial phase[76,77]. Apolipoprotein (APO) B is a large protein involved in the transport of triglycerides and cholesterol from the liver to peripheral tissues. Diminished synthesis of APO B, a rate-determining step in the very low density lipoproteins (VLDL) assembly, would impair the ability of the hepatocyte to export triglycerides and cholesterol esters. Impaired VLDL secretion would also result in increased levels of atherogenic triglyceride- and cholesterol-rich remnant particles. Recent studies have suggested a genetic basis for abnormal lipoprotein metabolism in patients with NAFLD. Two single-nucleotide polymorphisms in the gene encoding APOC3 may be associated with hypertriglyceridemia[78-80]. APOC3 variants C-482T and T-455C lead to increased plasma concentrations of APOC3, which in turn inhibit lipoprotein lipase and triglyceride clearance, thus conferring a predisposition to both fasting and postprandial hypertriglyceridemia due to an increase in chylomicron-remnant particles[81].
THERAPEUTIC APPROACH
The only accepted therapy for pediatric NAFLD is lifestyle modification with diet and physical exercise. The close association of NAFLD with MetS and obesity in children provides the rationale for the therapeutic role of weight reduction in the treatment of fatty liver disease. Fortunately, this approach may also be beneficial in improving cardiovascular risk profile.
Weight-loss oriented lifestyle interventions in the overweight pediatric population have been shown to increase glucose tolerance and improve the MetS risk factors[82]. In children with presumed NAFLD, several studies demonstrate a normalization of serum ALT associated with weight loss[5,83,84]. However, the relative efficacy of weight loss and degree of weight loss needed to induce histologic improvement in pediatric NAFLD is unknown. Studies in adults with NAFLD suggest that weight loss also leads to significant improvement in liver histology. In particular, a weight loss greater than 5% has been associated with significant improvement in liver histology[85]. There is only one clinical trial using liver histology as the primary end point in children and adolescents with NAFLD[83]. The study demonstrated that 2 years of lifestyle intervention with a diet tailored on individual caloric requirement and increased physical activity was associated with a mean weight loss of approximately 5 kg, resulting in a significant improvement in liver histology as well as in insulin resistance, serum levels of aminotransferases, and lipid levels. No information exists on recommending any type of diet. A low-carbohydrate diet has been shown to lead to a reduction in serum ALT and fatty liver content in adult patients[86]. A randomized controlled study in obese adolescents has demonstrated that a diet based on a reduced glycemic load is more effective than a low fat diet in achieving weight loss[87], but similar data are not available in children with NAFLD. Current data on the role of a low fructose diet in children with NAFLD are inconclusive[71]. A 6-month pilot study in children with NAFLD showed that a low fructose diet was associated with a significant decrease in oxidized LDL-c[88]. However, no effect on serum ALT concentrations was found. N-3 long-chain polyunsaturated fatty acids (LCPUFA) including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been reported to control some of the metabolic stigmata of obesity[89]. Dietary N-3 LCPUFA lower blood triglycerides and have anti-inflammatory as well as insulin-sensitizing effects[89]. A recent randomised clinical trial has shown that the supplementation of DHA improves liver steatosis and insulin sensitivity in children with NAFLD[90]. Their role in prevention of CVD is also emerging[91]. At this time, however, the available information is insufficient to derive dietary intake recommendations for EPA and DHA[92]. Finally, diet duration and amount of weight loss have not been definitively assessed in children[83,93,94].
A general consensus exists about the key role of physical activity and its synergic effect when combined to diet modifications. Increasing energy expenditure is an additional way to reducing daily calories. Liver biopsy has shown improvement of histologic features in children with NAFLD who were engaged in a moderate daily exercise program (45 min/d aerobic physical exercise) associated to dietary changes[83].
Owing to the likely role of insulin resistance and oxidative stress in the development and progression of NAFLD, most studies on pharmacological treatment have focused on the use of metformin or antioxidants. These drugs have been found to be effective in pilot studies[3]. Recently, in a multicenter, randomized, placebo-controlled clinical trial of treatment with metformin, vitamin E, or placebo for 96 wk in 173 nondiabetic children with histologically confirmed NAFLD, the Nonalcoholic Steatohepatitis Clinical Research Network found that compared with placebo, neither vitamin E nor metformin was associated with a sustained reduction in serum ALT[95,96]. Compared to placebo, vitamin E significantly improved hepatocellular ballooning and NAFLD activity score and, in the subset of children with NASH at baseline, significantly increased resolution of NASH. Metformin had no significant effect on any secondary histologic outcome[96]. Neither vitamin E nor metformin had significant effects on fibrosis, lobular inflammation, or portal inflammation scores. No significant differences in safety were reported between groups[96]. However, the likelihood that vitamin E would need to be taken indefinitely[97] underlines the importance of long-term prospective studies involving patients with NASH to assess the effect of vitamin E on liver-related and cardiovascular mortality[98].
Given the role of obesity in the pathogenesis of NAFLD, bariatric surgery has been proposed as a potential treatment strategy. In obese adult patients, bariatric surgery has been shown to induce weight loss, ameliorate cardiovascular risk factors, resolve hepatic steatosis and, in most studies, inflammation[99-101]. NASH was improved in the majority of affected patients and was intimately associated with insulin resistance over both the short and long term[101]. The issue of NAFLD and bariatric surgery in children is complex[71]. Though adolescents are increasingly undergoing surgical treatment of obesity, the guidelines for eligibility are not standardized[102]. In addition, children with a clinical diagnosis of NAFLD are different from those typically undergoing bariatric surgery[103]. Children with a clinical diagnosis of NAFLD tend to be younger and less obese than adolescents undergoing surgical treatment of obesity[103]. Although several studies report resolution or improvement of comorbidities after bariatric surgery in adolescents[104,105], liver outcome data are needed. In a series of 41 adolescents, Nadler et al[105] reported improvement in liver function enzymes 1 to 2 years after surgery.
CONCLUSION
The current body of evidence suggests that NAFLD is associated with a significantly greater overall mortality than in the general population, as well as with increased CVD prevalence, independently of classical atherosclerotic risk factors. These observations raise the possibility that NAFLD may be not only a marker but also an early mediator of atherosclerosis.
Children with NAFLD may also be at a higher risk for atherosclerosis. Therefore, the rising prevalence of obesity-related MetS and NAFLD in childhood may lead to a parallel increase in adverse cardiovascular outcomes. In children, the cardiovascular system remains plastic and damage-reversible if early and appropriate interventions are established effectively. Therapeutic goals for NAFLD should address nutrition, physical activity and avoidance of smoking to prevent not only end-stage liver disease but also CVD.
Footnotes
Peer reviewers: Eyvind J Paulssen, MD, PhD, Department of Gastroenterology, University Hospital of North Norway, PO Box 83, Tromsø, N-9038, Norway; Yoshihisa Takahashi, MD, Department of Pathology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
S- Editor Tian L L- Editor O’Neill M E- Editor Ma WH
References
1.
Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28:13-24.[PubMed] [DOI]
2.
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.[PubMed] [DOI]
3.
Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50:1282-1293.[PubMed]
4.
Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388-1393.[PubMed] [DOI]
5.
Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, Rubino A. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997;42:1428-1432.[PubMed] [DOI]
6.
Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. Int J Obes Relat Metab Disord. 2000;24:772-776.[PubMed] [DOI]
7.
Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Serum alanine aminotransferase activity in obese children. Acta Paediatr. 1997;86:238-241.[PubMed] [DOI]
8.
Chan DF, Li AM, Chu WC, Chan MH, Wong EM, Liu EK, Chan IH, Yin J, Lam CW, Fok TF. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord. 2004;28:1257-1263.[PubMed] [DOI]
9.
Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38.[PubMed] [DOI]
10.
Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:1325-1330.[PubMed] [DOI]
11.
Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22:1354-1358.[PubMed] [DOI]
12.
Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72-78.[PubMed] [DOI]
13.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.[PubMed] [DOI]
14.
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-121.[PubMed] [DOI]
15.
Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873.[PubMed] [DOI]
16.
Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234-238.[PubMed] [DOI]
17.
Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595-602.[PubMed] [DOI]
18.
Bland J, Skordalaki A, Emery JL. Early intimal lesions in the common carotid artery. Cardiovasc Res. 1986;20:863-868.[PubMed] [DOI]
19.
Stary HC. Lipid and macrophage accumulations in arteries of children and the development of atherosclerosis. Am J Clin Nutr. 2000;72:1297S-1306S.[PubMed]
20.
Newman WP, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med. 1986;314:138-144.[PubMed] [DOI]
21.
Wissler RW, Strong JP. Risk factors and progression of atherosclerosis in youth. PDAY Research Group. Pathological Determinants of Atherosclerosis in Youth. Am J Pathol. 1998;153:1023-1033.[PubMed] [DOI]
22.
Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650-1656.[PubMed] [DOI]
23.
Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, Mäki-Torkko N, Järvisalo MJ, Uhari M, Jokinen E, Rönnemaa T. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003;290:2277-2283.[PubMed] [DOI]
24.
Magnussen CG, Koskinen J, Chen W, Thomson R, Schmidt MD, Srinivasan SR, Kivimäki M, Mattsson N, Kähönen M, Laitinen T. Pediatric metabolic syndrome predicts adulthood metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus but is no better than body mass index alone: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study. Circulation. 2010;122:1604-1611.[PubMed] [DOI]
25.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923.[PubMed] [DOI]
26.
McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521-33, viii.[PubMed]
27.
Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129-1133.[PubMed] [DOI]
28.
Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005;16:421-427.[PubMed] [DOI]
29.
Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-335.[PubMed]
30.
Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang TT, Rosenthal P, Sanyal AJ, Schwimmer JB, Lavine JE. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2010;105:2093-2102.[PubMed] [DOI]
31.
Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond). 2008;32:381-387.[PubMed] [DOI]
32.
Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277-283.[PubMed] [DOI]
33.
Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106:15430-15435.[PubMed] [DOI]
34.
Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538-1544.[PubMed] [DOI]
35.
Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541-3546.[PubMed] [DOI]
36.
Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119-2121.[PubMed] [DOI]
37.
Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009;50:1403-1411.[PubMed] [DOI]
38.
Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579-1584.[PubMed]
39.
Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212-1218.[PubMed] [DOI]
40.
Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010;53:713-718.[PubMed] [DOI]
41.
Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol. 2005;11:4838-4842.[PubMed]
42.
Lautamäki R, Borra R, Iozzo P, Komu M, Lehtimäki T, Salmi M, Jalkanen S, Airaksinen KE, Knuuti J, Parkkola R. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;291:E282-E290.[PubMed] [DOI]
43.
Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473-480.[PubMed] [DOI]
44.
Targher G, Bertolini L, Padovani R, Poli F, Scala L, Zenari L, Zoppini G, Falezza G. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest. 2006;29:55-60.[PubMed]
45.
Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045-1050.[PubMed] [DOI]
46.
Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49:600-607.[PubMed] [DOI]
47.
Pacifico L, Anania C, Martino F, Cantisani V, Pascone R, Marcantonio A, Chiesa C. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52:1643-1651.[PubMed] [DOI]
48.
Lamotte C, Iliescu C, Libersa C, Gottrand F. Increased intima-media thickness of the carotid artery in childhood: a systematic review of observational studies. Eur J Pediatr. 2011;170:719-729.[PubMed] [DOI]
49.
Schwimmer JB, Deutsch R, Behling C, Lavine JE. Fatty liver as a determinant of atherosclerosis. Hepatology. 2005;42:(Suppl):610A.
50.
Pacifico L, Cantisani V, Ricci P, Osborn JF, Schiavo E, Anania C, Ferrara E, Dvisic G, Chiesa C. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res. 2008;63:423-427.[PubMed] [DOI]
51.
Demircioğlu F, Koçyiğit A, Arslan N, Cakmakçi H, Hizli S, Sedat AT. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2008;47:68-75.[PubMed] [DOI]
52.
Manco M, Bedogni G, Monti L, Morino G, Natali G, Nobili V. Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. Atherosclerosis. 2010;209:463-468.[PubMed] [DOI]
53.
Caserta CA, Pendino GM, Amante A, Vacalebre C, Fiorillo MT, Surace P, Messineo A, Surace M, Alicante S, Cotichini R. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol. 2010;171:1195-1202.[PubMed] [DOI]
54.
Kelishadi R, Cook SR, Amra B, Adibi A. Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis. 2009;204:538-543.[PubMed] [DOI]
55.
Weghuber D, Roden M, Franz C, Chmelik M, Torabia S, Nowotny P, Gruber S, Waldhäusl W, Klingler A, Bieglmayer C. Vascular function in obese children with non-alcoholic fatty liver disease. Int J Pediatr Obes. 2011;6:120-127.[PubMed] [DOI]
56.
Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A, Feldstein AE. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res. 2010;67:665-670.[PubMed] [DOI]
57.
Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.[PubMed] [DOI]
58.
McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am J Cardiol. 2005;96:399-404.[PubMed] [DOI]
59.
Quijada Z, Paoli M, Zerpa Y, Camacho N, Cichetti R, Villarroel V, Arata-Bellabarba G, Lanes R. The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatr Diabetes. 2008;9:464-471.[PubMed] [DOI]
60.
Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.[PubMed] [DOI]
61.
Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241.[PubMed] [DOI]
62.
Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007;27:423-433.[PubMed] [DOI]
63.
Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa?. Dig Liver Dis. 2010;42:320-330.[PubMed] [DOI]
64.
Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169-2180.[PubMed] [DOI]
65.
Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev. 2008;29:939-960.[PubMed] [DOI]
66.
Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19:371-379.[PubMed] [DOI]
67.
Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004;99:1497-1502.[PubMed] [DOI]
68.
Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu SY, Erdil A, Ates Y, Aslan M. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2005;100:850-855.[PubMed]
69.
Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring). 2008;16:1394-1399.[PubMed]
70.
Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, Johnson RJ, Abdelmalek MF. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48:993-999.[PubMed] [DOI]
71.
Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB. Pediatric nonalcoholic fatty liver disease: a comprehensive review. Adv Pediatr. 2010;57:85-140.[PubMed] [DOI]
72.
Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7:251-264.[PubMed] [DOI]
73.
Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119:1322-1334.[PubMed] [DOI]
74.
Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006;367:36-47.[PubMed] [DOI]
75.
Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol. 2006;17:412-417.[PubMed] [DOI]
76.
Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Fagà E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909-916.[PubMed] [DOI]
77.
Musso G, Cassader M, Gambino R, Durazzo M, Pagano G. Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. Hepatology. 2006;43:1169-1170.[PubMed] [DOI]
78.
Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res. 2003;44:2374-2381.[PubMed] [DOI]
79.
Olivieri O, Stranieri C, Bassi A, Zaia B, Girelli D, Pizzolo F, Trabetti E, Cheng S, Grow MA, Pignatti PF. ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res. 2002;43:1450-1457.[PubMed] [DOI]
80.
Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K, Dwivedi M, Misra A. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res. 2007;38:444-451.[PubMed] [DOI]
81.
Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082-1089.[PubMed]
82.
Monzavi R, Dreimane D, Geffner ME, Braun S, Conrad B, Klier M, Kaufman FR. Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics. 2006;117:e1111-e1118.[PubMed] [DOI]
83.
Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48:119-128.[PubMed] [DOI]
84.
Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, Sartorelli MR, Angulo P. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458-465.[PubMed] [DOI]
85.
Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603-608.[PubMed] [DOI]
86.
Benjaminov O, Beglaibter N, Gindy L, Spivak H, Singer P, Wienberg M, Stark A, Rubin M. The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery. Surg Endosc. 2007;21:1423-1427.[PubMed] [DOI]
87.
Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS. A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med. 2003;157:773-779.[PubMed] [DOI]
88.
Vos MB, Weber MB, Welsh J, Khatoon F, Jones DP, Whitington PF, McClain CJ. Fructose and oxidized low-density lipoprotein in pediatric nonalcoholic fatty liver disease: a pilot study. Arch Pediatr Adolesc Med. 2009;163:674-675.[PubMed] [DOI]
89.
Klein-Platat C, Drai J, Oujaa M, Schlienger JL, Simon C. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr. 2005;82:1178-1184.[PubMed]
90.
Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli C, Agostoni C. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96:350-353.[PubMed]
91.
Calder PC, Dangour AD, Diekman C, Eilander A, Koletzko B, Meijer GW, Mozaffarian D, Niinikoski H, Osendarp SJ, Pietinen P. Essential fats for future health. Proceedings of the 9th Unilever Nutrition Symposium, 26-27 May 2010. Eur J Clin Nutr. 2010;64 Suppl 4:S1-13.[PubMed]
92.
Koletzko B, Uauy R, Palou A, Kok F, Hornstra G, Eilander A, Moretti D, Osendarp S, Zock P, Innis S. Dietary intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in children - a workshop report. Br J Nutr. 2010;103:923-928.[PubMed] [DOI]
93.
Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Effect of weight reduction on serum transaminase activities in children with simple obesity. J Pediatr. 1996;128:587-588.[PubMed] [DOI]
94.
Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child. 2009;94:437-442.[PubMed] [DOI]
95.
Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials. 2010;31:62-70.[PubMed] [DOI]
96.
Lavine JE, Schwimmer JB, Molleston JP, Chalasani NP, Rosenthal P, Murray KF, Abrams SH, Scheimann AO, Sanyal AJ, Brunt EM. Vitamin E, Metformin or placebo for treatment of nonalcoholic fatty liver disease in children. Hepatology. 2010;52 Supp l:110A.[PubMed] [DOI]
97.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.[PubMed] [DOI]
98.
Armstrong MJ, Houlihan DD, Rowe IA. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;363:1185; author reply 1186.[PubMed] [DOI]
99.
Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142:547-559.[PubMed]
100.
Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.[PubMed]
101.
Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532-540.[PubMed]
102.
Pratt JS, Lenders CM, Dionne EA, Hoppin AG, Hsu GL, Inge TH, Lawlor DF, Marino MF, Meyers AF, Rosenblum JL. Best practice updates for pediatric/adolescent weight loss surgery. Obesity (Silver Spring). 2009;17:901-910.[PubMed] [DOI]
103.
Pardee PE, Lavine JE, Schwimmer JB. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg. 2009;18:144-151.[PubMed] [DOI]
104.
Nadler EP, Youn HA, Ren CJ, Fielding GA. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. J Pediatr Surg. 2008;43:141-146.[PubMed] [DOI]
105.
Nadler EP, Reddy S, Isenalumhe A, Youn HA, Peck V, Ren CJ, Fielding GA. Laparoscopic adjustable gastric banding for morbidly obese adolescents affects android fat loss, resolution of comorbidities, and improved metabolic status. J Am Coll Surg. 2009;209:638-644.[PubMed] [DOI]